Chimeric Therapeutics Limited (CHM.AX)

AUD 0.01

(-14.29%)

Market Cap (In AUD)

9.45 Million

Revenue (In AUD)

7.45 Million

Net Income (In AUD)

-12.52 Million

Avg. Volume

1.17 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.006-0.043
PE
-
EPS
-
Beta Value
1.593
ISIN
AU0000121576
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
Employee Count
-
Website
https://www.chimerictherapeutics.com
Ipo Date
2021-01-17
Details
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.